Europe and the supply of innovative medicines: why it matters

One of the standout features of the ‘no-deal’ Brexit debate has been the focus on the impact on supplies of medicines and medicinal products. This includes everything from chemical compounds and investigational medicinal products (IMPs) for clinical research through to short shelf-life medicines made on the continent. The debate has been a continuous battle between those outlining the possible impact on patients’ lives while struggling to quantify the extent of the impact. Some areas...